Versartis Publishes Preclinical Abstracts For Two Product Candidates At 2009 American Diabetes Association Scientific Sessions

Versartis Publishes Preclinical Abstracts For Two Product Candidates At 2009 American Diabetes Association Scientific Sessions
Versartis, Inc., a new company developing novel biologics with enhanced properties for patients with metabolic diseases, published abstracts for preclinical data on its two product candidates, VRS-859 (exenatide-rPEG) and VRS-808 (glucagon-rPEG), at the American Diabetes Association Scientific Sessions annual meeting beginning today in New Orleans. Versartis, through a unique licensing agreement with Amunix, Inc.